Feasibility of mini-tablets as a flexible drug delivery tool.

Mini-tablets have potential applications as a flexible drug delivery tool in addition to their generally perceived use as multi-particulates. That is, mini-tablets could provide flexibility in dose finding studies and/or allow for combination therapies in the clinic. Moreover, mini-tablets with well controlled quality attributes could be a prudent choice for administering solid dosage forms as a single unit or composite of multiple mini-tablets in patient populations with swallowing difficulties (e.g., pediatric and geriatric populations). This work demonstrated drug substance particle size and concentration ranges that achieve acceptable mini-tablet quality attributes for use as a single or composite dosage unit. Immediate release and orally disintegrating mini-tablet formulations with 30µm to 350µm (particle size d90) acetaminophen and Compap™ L (90% acetaminophen) at concentrations equivalent to 6.7% and 26.7% acetaminophen were evaluated. Mini-tablets achieved acceptable weight variability, tensile strength, friability, and disintegration time at a reasonable solid fraction for each formulation. The content uniformity was acceptable for mini-tablets of 6.7% formulations with ≤170µm drug substance, mini-tablets of all 26.7% formulations, and composite dosage units containing five or more mini-tablets of any formulation. Results supported the manufacturing feasibility of quality mini-tablets, and their applicability as a flexible drug delivery tool.

A novel sample selection strategy by near-infrared spectroscopy-based high throughput tablet tester for content uniformity in early-phase pharmaceutical product development.

This article proposes a new sample selection strategy to simplify the traditional content uniformity (CU) test in early research and development (R&D) with improved statistical confidence. This strategy originated from the prescreening of a large amount of tablets by a near-infrared spectroscopy (NIRS)-based high-volume tablet tester to the selection of extreme tablets with highest, medium, and lowest content of active pharmaceutical ingredient (API) for further high-performance liquid chromatography (HPLC) test. The NIRS-based high-volume tablet tester was equipped with an internally developed and integrated automated bagging and labeling system, allowing the traceability of every individual tablet by its measured physical and chemical signatures. A qualitative NIR model was used to translate spectral information to a concentration-related metric, that is scores, which allowed the selection of those extreme tablets. This sample selection strategy of extreme tablets was shown to provide equivalent representation of CU in the process compared with the traditional CU test using a large number of random samples. Because it only requires reference tests on three extreme samples per stratified location, the time- and labor-saving nature of this strategy is advantageous for CU test in early R&D. The extreme sampling approach is also shown to outperform random sampling with respect to statistical confidence for representing the process variation. In addition, a chemometric approach, which utilizes only pure component raw materials to develop an NIRS model sensitive to API concentration, is discussed with the advantage that it does not require tablets at multiple API levels. Prospective applications of this sample selection strategy are also addressed.